Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-116 in Advanced Solid Tumors
NCT06782334Phase 2Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-116 in solid tumor (advanced stage), sponsored by Multitude Therapeutics. Started May 2024; status: recruiting.
02
Drugs
AMT-116
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06782334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782334.